Patient characteristics | Antimicrobials after iCDI treatment modeled as time dependent variables | Antimicrobials after iCDI treatment modeled as time independent variables | ||
---|---|---|---|---|
Risk factor | Hazard ratio | 95% CI | Hazard ratio | 95% CI |
At admission to the hospital | ||||
CDI case status | ||||
HO CDI | Ref | Ref | ||
COHCFA CDI | 1.80 | 1.41-2.29 | 1.78 | 1.39-2.27 |
CA CDI | 1.30 | 0.95-1.80 | 1.25 | 0.91-1.72 |
Number of hospitalizations in previous 60 days | ||||
None | Ref | |||
1 | 1.25 | 0.97-1.61 | 1.27 | 0.99-1.64 |
>1 | 1.40 | 1.04-1.89 | 1.46 | 1.08-1.96 |
Age (per 1 year) | 1.01 | 1.00-1.02 | 1.01 | 1.00-1.02 |
At the onset or during treatment of iCDI | ||||
Gastric acid suppression | 1.36 | 1.00-1.85 | 1.40 | 1.03-1.90 |
Cumulative fluoroquinolone exposurea | 1.24 | 1.09-1.41 | 1.42 | 1.25-1.61 |
Following completion of iCDI treatment | ||||
High risk antimicrobialb | 2.95c | 2.25-3.86 | 1.86 | 1.42-2.42 |
Fluoroquinolone | 1.56c | 1.63-2.08 | 0.86 | 0.64-1.15 |
IV vancomycin | 1.45c | 1.09-1.92 | 1.05 | 0.80-1.39 |